Venture Life Group (LON:VLG) Hits New 52-Week High – What’s Next?

Posted by Latisha Jones on Dec 18th, 2025

Venture Life Group plc (LON:VLG – Get Free Report)’s stock price hit a new 52-week high during trading on Thursday . The company traded as high as GBX 67 and last traded at GBX 66.25, with a volume of 326740 shares. The stock had previously closed at GBX 65.

Venture Life Group Trading Up 1.9%

The company has a market cap of £84.54 million, a P/E ratio of -87.17, a PEG ratio of 5.67 and a beta of 0.30. The firm’s 50 day moving average is GBX 57.67 and its two-hundred day moving average is GBX 57.01. The company has a quick ratio of 1.48, a current ratio of 2.22 and a debt-to-equity ratio of 28.45.

Venture Life Group (LON:VLG – Get Free Report) last announced its earnings results on Tuesday, September 30th. The company reported GBX 0.83 earnings per share (EPS) for the quarter. Venture Life Group had a return on equity of 0.99% and a net margin of 1.44%. As a group, equities research analysts anticipate that Venture Life Group plc will post 6.1391542 EPS for the current year.

Insider Activity at Venture Life Group

In related news, insider Mark Adams acquired 88,999 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The shares were bought at an average cost of GBX 56 per share, with a total value of £49,839.44. 6.84% of the stock is currently owned by corporate insiders.

Venture Life Group Company Profile

(Get Free Report)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market.

With operations in the UK, The Netherlands and Italy, the Group’s product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women’s intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples.